Account Info
Log Out
  • English
  • 中文繁体
  • 中文简体

Absci (NASDAQ:ABSI) Trading 1% Higher

Defense World ·  01/25 16:12

Absci Co. (NASDAQ:ABSI – Get Rating)'s share price traded up 1% during trading on Tuesday . The company traded as high as $3.25 and last traded at $3.12. 466,859 shares were traded during trading, a decline of 0% from the average session volume of 468,491 shares. The stock had previously closed at $3.09.

Absci Stock Performance

The company has a market cap of $288.27 million, a PE ratio of -2.54 and a beta of 0.62. The company has a debt-to-equity ratio of 0.03, a current ratio of 6.71 and a quick ratio of 6.71. The business has a 50-day moving average of $2.48 and a 200 day moving average of $3.12.

Get Absci alerts:

Absci (NASDAQ:ABSI – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). The firm had revenue of $2.37 million for the quarter, compared to analysts' expectations of $1.79 million. Absci had a negative net margin of 1,960.28% and a negative return on equity of 33.62%. Equities research analysts anticipate that Absci Co. will post -1.13 EPS for the current fiscal year.

Institutional Trading of Absci

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Metropolitan Life Insurance Co NY purchased a new stake in Absci in the first quarter worth about $33,000. Two Sigma Advisers LP purchased a new stake in shares of Absci during the third quarter worth about $34,000. Ameritas Investment Partners Inc. grew its position in shares of Absci by 305.3% during the first quarter. Ameritas Investment Partners Inc. now owns 4,312 shares of the company's stock worth $36,000 after purchasing an additional 3,248 shares in the last quarter. ProShare Advisors LLC purchased a new stake in shares of Absci during the third quarter worth about $42,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Absci during the second quarter worth about $43,000. Hedge funds and other institutional investors own 47.59% of the company's stock.

Absci Company Profile

(Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.

Read More

  • Get a free copy of the research report on Absci (ABSI)
  • Is It Time To Get Aggressive With Defense Stocks?
  • 3 Retail Stocks Ringing the Register in 2023
  • When Will Crane Holdings Take Flight?
  • EVgo Stock is Charged Up to Ride the EV Adoption Wave
  • Qualcomm Gets a Boost from Analysts, but is it Time to Buy?

Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites and Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.